0.00Open0.00Pre Close0 Volume0 Open Interest3.00Strike Price0.00Turnover0.00%IV60.73%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma10.19Leverage Ratio--Theta--Rho--Eff Leverage--Vega
BioCryst Pharmaceuticals Stock Discussion
—Q1 2024 ORLADEYO net revenue grows 30 percent y-o-y to $88.9 million—
—Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidance range) —
—Pipeline programs, including BCX17725 for Netherton syndrome and avoralstat for DME, advancing on schedule into clinical trials—
NEWS
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
BioCryst Pharmaceuticals, Inc., a leading American biotechnology company, has presented new real-world data that shows significant and sustained reductions in hereditary angioedema (HAE) attack rates after patients began treatment with ORLADEYO® (berotralstat). This groundbreaking development could have far-reaching imp...
No comment yet